A peptide-based assay discriminates individual antibody response to SARS-CoV-2

SARS-CoV-2 virus is responsible for the current worldwide coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. Understanding the antibody response to SARS-CoV-2 is crucial for the development of vaccines, therapeutics and public heal...

Full description

Saved in:
Bibliographic Details
Published in:Genes & diseases 2022-01, Vol.9 (1), p.275-281
Main Authors: Polvere, Immacolata, Voccola, Serena, Cardinale, Gaetano, Fumi, Maurizio, Aquila, Francesca, Parrella, Alfredina, Madera, Jessica Raffaella, Stilo, Romania, Vito, Pasquale, Zotti, Tiziana
Format: Article
Language:English
Subjects:
Antibodies
Assay
COVID-19
ELISA
Full Length
Peptides
SARS-Cov-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SARS-CoV-2 virus is responsible for the current worldwide coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. Understanding the antibody response to SARS-CoV-2 is crucial for the development of vaccines, therapeutics and public health interventions. However, lack of consistency in methods used to monitor antibody response to SARS-CoV-2 leaves some uncertainty in our fine understanding of the human antibody response mounted following SARS-CoV-2 infection. We developed a peptide-based enzyme-linked immunosorbent assay (ELISA) by selecting 7 synthetic peptides from the spike, membrane, and nucleocapsid protein sequences of SARS-CoV-2, which effectively detects the antibody response mounted by all COVID-19 convalescent tested. Strikingly, the assay shows a profound difference in antibody response among individual subjects, which may have a significant impact on disease severity. Together, our results define an efficient and specific serological assay to consistently measure the antibody response following SARS-CoV-2 infection, as well as help the design of vaccine and therapeuticals for prevention and treatment of COVID-19.
ISSN:2352-3042
2352-4820
2352-3042
DOI:10.1016/j.gendis.2021.01.008